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Objective: Thoracoabdominal aortic aneurysm operations are associated with extensive blood loss and high
requirements for allogeneic blood product transfusion. We assessed the efficacy of intraoperative post–cardiopul-
monary bypass administration of fibrinogen concentrate in elective thoracoabdominal aortic aneurysm surgery.
Methods: In a retrospective group (group A, n ¼ 12) of patients undergoing elective thoracoabdominal aortic
aneurysm surgery, clinically relevant diffuse bleeding after weaning from cardiopulmonary bypass was treated
with allogeneic blood products (platelet concentrates, followed by fresh frozen plasma) according to a predeter-
mined algorithm.
In a prospective group (group F, n¼ 6) a first therapy step with fibrinogen concentrate was added to the algorithm.
The dose of fibrinogen concentrate was estimated by using thromboelastometric data (ROTEM FIBTEM). Before
each step of hemostatic therapy, blood loss in the range of 60 to 250 g per 5 minutes was confirmed.
Results: In group F, administration of 7.8  2.7 g of fibrinogen concentrate established hemostasis, completely
avoiding intraoperative transfusion of fresh frozen plasma and platelet concentrates. Transfusion of blood prod-
ucts after cardiopulmonary bypass and during the 24 hours after surgical intervention was markedly lower in
group F than in group A (2.5 vs 16.4 units; 4/6 patients in group F required no transfusion of blood products),
as was 24-hour drainage volume (449 vs 1092 mL). Fibrinogen plasma levels, standard coagulation parameters,
and hemoglobin and hematocrit values were comparable between the 2 groups on the first postoperative day.
Conclusions: FIBTEM-guided post–cardiopulmonary bypass administration of fibrinogen concentrate resulted
in improved intraoperative management of coagulopathic bleeding in thoracoabdominal aortic aneurysm opera-
tions and reduced transfusion and 24-hour drainage volume.Thoracoabdominal aortic aneurysm (TAAA) operations are
frequently complicated by excessive perioperative bleeding,
most commonly caused by impairment of the coagulation
system.1Patientswith aortointimal disease are in ahyperfibri-
nolytic state because of abnormal endothelial expression of
tissue plasminogen activator, which correlates with the
chronic consumption coagulopathy accompanying aortic an-
eurysm.2 Extracorporeal circulation (ECC) exerts an addi-
tional deleterious effect on hemostasis through activation
of coagulation and fibrinolysis, consumption coagulopathy,
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hances the risk of rethoracotomy, transfusion, or periopera-
tive myocardial infarction, leading to increased morbidity
and mortality.5 Although TAAA surgery has improved
over recent years, the perioperative consumption of alloge-
neic blood products and the risk of bleeding remain high.6
The standard hemostatic treatment is transfusion of nonery-
throcyte allogeneic blood products: fresh frozenplasma (FFP),
platelet concentrates (PCs), and, in some countries, cryopreci-
pitate. However, there is an inherent risk of transmission of
pathogens with transfusion of allogeneic blood products,
which can be associated with serious adverse effects.7,8 Pre-
emptive transfusion, in which blood products are transfused
before laboratory abnormalities are recognized, plays a central
role in the intraoperative transfusion strategy for TAAA oper-
ations and has shown improved outcome comparedwith treat-
ment algorithms based on laboratory measurements.9
The possibilities for reducing transfusion of allogeneic
blood products after cardiac surgery have been investigated
recently. Assessment of clot formation and strength, mea-
sured by using viscoelastic methods (thromboelastography
[TEG] or thromboelastometry [ROTEM]), is useful for
the diagnosis of intraoperatively acquired coagulationgery c September 2009
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CPB ¼ cardiopulmonary bypass
ECC ¼ extracorporeal circulation
EXTEM ¼ ROTEM test with extrinsic activation
of coagulation
FFP ¼ fresh frozen plasma
FIBTEM ¼ ROTEM test with extrinsic activation
of coagulation and platelet inhibition
with cytochalasin D
ICU ¼ intensive care unit
MCF ¼ maximum clot firmness
PC ¼ platelet concentrate
RBC ¼ red blood cell
ROTEM ¼ thromboelastometry
TAAA ¼ thoracoabdominal aortic aneurysm
TEG ¼ thromboelastography
disturbances and has resulted in the development of coagu-
lation therapy algorithms and consequent reductions in
blood transfusion and associated hospitalization costs.10,11
Administration of coagulation factor concentrates might
also support the reduction of perioperative transfusion. Hae-
mocomplettan P (CSL Behring, Marburg, Germany) is a pu-
rified, virus-inactivated fibrinogen concentrate obtained
from lyophilized plasma. Fibrinogen concentrate was used
initially for replacement therapy in inherited fibrinogen de-
ficiencies but might also correct the fibrinogen deficit asso-
ciated with bleeding after cardiac surgery.4,12
This prospective trial assesses the efficacy of intraoperative
coagulation therapy with thromboelastometry-guided fibrino-
gen concentrate by using a strict transfusion algorithm applied
in ahomogenous groupofpatients undergoingTAAAsurgery.
MATERIALS AND METHODS
The study protocol was approved by the Institutional Review Board of
Hannover Medical School, and written informed consent was obtained
from the patients enrolled in the prospective arm of the study.
Patients
The retrospective group (group A, allogeneic blood products) included
all patients who underwent elective TAAA surgery in Hannover Medical
School during 2006 with none of the exclusion criteria listed below (n ¼
12). Our center uses a standard transfusion algorithm for the treatment of
intraoperative clinically relevant diffuse bleeding occurring after cardiopul-
monary bypass (CPB), consisting of the administration of PCs and FFP.
For the prospective group (group F, fibrinogen), consisting of 6 patients
undergoing elective TAAA surgery, the administration of fibrinogen con-
centrate (Haemocomplettan P, CSL Behring) was added as step 0 to the
algorithm of hemostatic therapy (Figure 1).
Exclusion criteria for bothgroups includedpositive anamnesis of bleeding,
age less than 18 years, pregnancy, myocardial infarction in the past 3 months,
reported platelet aggregation inhibitor therapy within 5 days of surgical inter-
vention, emergency status, and reoperation. As end points after ECC and 24-
hour intensive care unit (ICU) treatment, use of blood products and 24-hour
postoperative drainage volume data were collected in both groups.The Journal of Thoracic and CAssessment of Bleeding Mass
After weaning from ECC, neutralization of heparin, and completion of
surgical hemostasis, all blood was removed from the wound area with a suc-
tion device. The dry wound area was then thoroughly covered with sterile,
dry surgical swabs. After a short period of time (not exactly defined in group
A), the surgical swabs were removed to estimate the amount and location of
bleeding. In group A the level of bleeding was estimated by the surgeons
and the anesthetist and was characterized as low, high, or excessive.
High-level bleeding was treated according to the transfusion algorithm,
and excessive bleeding required surgical re-exploration.
In group F packing of surgical swabs was restricted to exactly 5 minutes to
support an accurate measurement of the blood loss. The extent of blood loss
was determined bymeasuring the difference in weight of the swabs before ap-
plication and after 5minutes of adsorbing blood. Blood loss of 60 to 250 gwas
defined as high-level bleeding and thus represented the trigger for coagulation
therapy. Patientswith blood loss of less than 60g receivedno therapy,whereas
blood loss of greater than 250 g was considered to be of surgical origin requir-
ing surgical re-exploration. The procedure was repeated after surgical re-ex-
ploration and after each step of hemostatic therapy to determine whether
further steps were necessary. The cutoff values applied for the diagnosis of
clinically relevant microvascular bleeding (60–250 g) were based on our pre-
vious experience in TAAA surgery and are not described in the literature.
Introduction of the Therapy Step With Fibrinogen
Concentrate Into the Standard Transfusion
Algorithm
Based on the observation that post-ECC platelet counts in patients with
TAAA are usually less than 100,000/mL, group A received PCs as the first
line of therapy when clinically relevant bleeding was observed after CPB.
This was followed by therapy with FFP if bleeding persisted at a high level.
Further transfusion steps consisted of concomitant transfusion of FFP and
PCs. The efficacy of the therapy stepswas assessed byusing dry surgical swabs.
Patients prospectively enrolled in group F and presenting with measured
blood loss of 60 to 250 g were treated according to the treatment algorithm de-
scribed in Figure 1. Before the administration of PCs or FFP, the administra-
tion of fibrinogen concentrate (HaemocomplettanP)was introduced (step 0) to
obtain a maximum clot firmness (MCF) of 22 mm in the FIBTEM thromboe-
lastometry test. The rationale for choosing this target value within the normal
range for FIBTEMMCFwas to balance the reduction of fibrinogen caused by
the operation. A FIBTEMMCF of 22mm correlates with a plasma fibrinogen
level of 3.6 g/L, which is within normal values for older populations.13
This therapeutic stepwas followed by reevaluation of the 5-minute bleed-
ingmass. If blood loss had remained greater than 60 g, additional transfusion
of PCs or FFPwould have been administered depending on the platelet count
at the last suture time point (Figure 1). If bleeding had persisted after the 3
consecutive therapy steps described above, further steps of therapy would
have consisted of 2 units of FFP and 1 unit of PC. Successful therapy was
defined as blood loss of less than 60 g after the final therapy step.
The transfusion of red blood cell (RBC) concentrates was adjusted to
maintain hematocrit levels of 23% to 25% during CPB, reaching 27% after
CPB when the blood from the ECC system was reinfused into the patient,
which is in line with the clinic’s standard procedure.
Fibrinogen Concentrate Dosing Based on Specific
Point-of-Care Measurements
The dose of fibrinogen concentrate was calculated based on the value of
the MCF parameter in the FIBTEM thromboelastometry test performed at
the last suture time point by using the following formula:
Fibrinogen concentrate ðgÞ ¼ ð22 ½mmFIBTEM
MCF ½mmÞ3Body weight ðkgÞ3 c
ðwhere C ¼ 0:5 ½g=ð1 ½mm3 70 ½kgÞardiovascular Surgery c Volume 138, Number 3 695
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weight=140. According to this formula, a patient of 70 kg requires a fibrinogen
concentrate dose of approximately 0.5 g to increase FIBTEMMCF by approx-
imately 1 mm.
The result was rounded to a whole number of grams of fibrinogen con-
centrate. The upper acceptable limit for MCF in the EXTEM thromboelas-
tometry test was set at 68 mm to minimize the risk of thrombotic
complications. Although there is no report of ROTEM values predictive
of thrombosis, a value of greater than 68 mm of the maximum amplitude
of the clot determined by using TEG was shown to be predictive of throm-
botic complications.14 Because ROTEMMCF values are normally slightly
higher than those obtained by using TEG,15 68mm represents a conservative
upper limit.
End Points to Evaluate the Efficacy of Fibrinogen
Concentrate
The primary end point for evaluation of the efficacy of fibrinogen
concentrate was the transfusion of allogeneic blood products intraopera-
tively after CPB and during the 24 hours postoperatively. Secondary end
points included the number of patients without any transfusion during
this timeframe and 24-hour postoperative blood loss (24-hour drainage
value).
FIGURE 1. Flow chart of transfusion algorithm. Platelet count is ex-
pressed as 1000/mL. PLT, Platelet count measured at the last suture time
point (the suture of the last collateral artery on the aortic graft); FFP, fresh
frozen plasma; PC, platelet concentrates.696 The Journal of Thoracic and Cardiovascular SurOperative and Anesthetic Management
All patients in groups A and F underwent general anesthesia induced with
etomidate, 0.3 mg/kg; fentanyl, 8 mg/kg; and cisatracurium, 0.2 mg/kg. During
induction of anesthesia, patients received 500 mL of lactated Ringer’s solution
and 500mLof gelatin polysuccinate (Gelafundin 0.026; Serumwerk, Bernburg,
Germany), according to the clinic’s standard procedures. The trachea was intu-
bated with a double-lumen tracheal tube, and the patients were placed in a right
lateral decubitus position. For maintenance of anesthesia, sevoflurane was
titrated to an end-tidal concentration of 1% to 2% until institution of ECC.
Propofol was infused at 50 to 80mg kg1 min1, and 4mg/kg boluses of fentanyl
were administered every 30 minutes for the duration of ECC. A lumbar spinal
drain was placed routinely for control of the intraspinal liquid pressure.
All patients underwent the same surgical technique. After administra-
tion of pig mucosal heparin (400 IU/kg) and cannulation of the femoral
artery and vein, ECC on a standard CPB device (Sto¨ckert SIII; Sto¨ckert
Instruments, Munich, Germany) was established, and a proximal anasto-
mosis between the descending aorta and the artificial graft (Hemashield
Gold or Platin, Woven Double Velour Vascular Graft; Boston Scientific
International SA, Boston, Mass) was performed. Distal anastomosis was
completed by means of decannulation of the femoral vein and artery
with concomitant protamine sulfate administration. Light hypothermia of
34C was used in all patients. Both groups received 1 million kalli-
krein-inhibiting units of aprotinin before ECC and a further 1 million kal-
likrein-inhibiting units of aprotinin added to the ECC priming solution.
After the initial anticoagulation, additional doses of heparin were admin-
istered to maintain an activated clotting time of more than 480 seconds
(ACT Plus; Medtronic, Minneapolis, Minn). The system was primed
with 1000 mL of Ringer’s lactate solution, 500 mL of sodium chloride,
and 40 mL of sodium bicarbonate (8.4%). At the end of ECC, heparin
was neutralized with protamine sulfate, 1 mg of protamine for every
100 U of the total heparin dose; an activated clotting time of less than
150 s indicated reversal of the effects of heparin.
Hematologic Tests
Serial blood samples were drawn from a radial artery catheter (20 gauge)
into Sarstedt collection vials (Sarstedt, Nuembrecht, Germany) containing
heparin, citrate, or ethylenediamine tetra-acetic acid as anticoagulant. Blood
was sampled at the beginning of the operation (before induction of anesthe-
sia), at the last suture time point (the suture of the last collateral artery on the
aortic graft), at the end of ECC, after each therapy step, and 24 hours after
the operation.
Activated partial thromboplastin time (APTT Kaolin; STAGO Diagnos-
tica, Asnieres, France), prothrombin time (Neoplastin, STAGO Diagnos-
tica), and fibrinogen concentration (Clauss method: optical read-out) were
determined by using the STA-R Analyzer (STAGO Diagnostica). Platelet
counts and hematocrit values were measured on the Sysmex XE-2100
(Roche Diagnostics, Mannheim, Germany). Platelet counts were available
within 10 to 15 minutes.
A 4-channel ROTEM device (Pentapharm, Munich, Germany) was used
for thromboelastometric analyses of the blood samples, as previously de-
scribed.10 For each test, the reagents and the blood are pipetted semiauto-
matically into a single-use plastic cup that is then set onto a plastic pin on
a rotating vertical axis guided by ball bearings. The increasing firmness
of the clot gradually reduces the movement of the pin. This is continuously
detected by using a light source, a reflecting mirror on the rotating axis, and
a sensor chip. The reduction in movement is mathematically transformed
into clot firmness (amplitude in millimeters) and plotted against time (in sec-
onds), resulting in a thromboelastometric trace. ROTEM tests were per-
formed with 300 mL of citrated whole blood and 20 mL of 0.2 mol/L
calcium chloride together with specific activators. In the standard global
tests to measure clot strength, the activators used were 20 mL of rabbit brain
thromboplastin (ex-TEM reagent) for the EXTEM test and 20 mL of ellagic
acid and rabbit brain partial thromboplastin phospholipid (in-TEM reagent)
for the INTEM test. In the FIBTEM test cytochalasin D (fib-TEM reagent)gery c September 2009
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the formation of the clot. Clotting time (in seconds; time from the start of the
test until the amplitude of 2 mm is detected), clot formation time (in sec-
onds; time for the clot to develop from 2 to 20 mm), MCF (in millimeters),
and the alpha angle (the opening angle of the trace) were recorded. Typical
EXTEMand FIBTEM thromboelastometric traces are presented in Figure 2.
Statistical Analysis
The data were analyzed for differences between groups with regard to the
preoperative variables, the intraoperative and 24-hour postoperative transfu-
sion of allogeneic blood products, and the 24-hour postoperative blood loss.
Data are presented as the mean  first standard deviation of the individual
determinations. Continuous variables were analyzed by using the Mann–
WhitneyU test, and categorical variables were analyzed by using the c2 test.
RESULTS
Groups A and F were comparable with regard to preoper-
ative characteristics (Table 1). There were more female
patients in the allogeneic blood products group (group A,
42%) compared with the fibrinogen concentrate group
(group F, 12%), but this difference was not statistically sig-
nificant (P ¼ .079). For group F, the main parameters guid-
ing the first step of therapy consisted of platelet count
(92,500 37,310/mL) before the suture of the last collateral
artery on the vascular graft (FIBTEM MCF was 8.3  4.6
mm at this time point) and the 5-minute blood loss (136.5
 86.9 g) after weaning from ECC and after surgical hemo-
stasis. After administration of a mean dose of fibrinogen
concentrate of 7.8  2.7 g (range, 5–13 g), the 5-minuteThe Journal of Thoracic and Cblood loss decreased to 42.0  8.9 g, with the result that
these patients required only this single therapeutic step.
Even though the intraoperative use of RBC concentrates
was significantly less in group F (1.3  1 units vs 8.3  3
units in group A), the hematocrit values were comparable
in the 2 groups at all times. The total amount of allogeneic
blood products transfused intraoperatively after weaning
from ECC and in the first 24-hour postoperative period
was significantly less in group F (2.5  4.3 units compared
with 16.4 4.8 units in group A, Table 2). Four of the 6 pa-
tients in group F required no transfusion of allogeneic blood
products after weaning from ECC or in the first 24 hours
postoperatively, whereas all patients in group A required
allogeneic blood product transfusion.
Therewere differences between the 2 groups in parameters
measured during the postoperative period. Patients in group
F had significantly lower 24-hour drainage volumes in the
ICU (449.2  181.7 mL compared with 1092.5  593.9
mL in group A). Also, intubation time in the ICU and the du-
ration of stay in the ICUwere significantly shorter in group F.
The total number of hospitalization days was comparable be-
tween groups (Table 2). One (20.0%) of the 5 patients in
group F and 5 (41.7%) of the 12 patients in group A required
prolonged respiratory assistance. No other complications
occurred within group F; complications within group A
weremajor neurologic events (2 patients), renal failure (2 pa-
tients), and in-hospital death (2 patients). Four patients inP
MA
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FIGURE 2. Examples of thromboelastometry curves (ROTEM). A, Traces before fibrinogen concentrate therapy. The upper MCF limit of 68 mm is indi-
cated by a solid line. B, Traces after fibrinogen concentrate therapy. MCF, Maximum clot firmness; EXTEM, ROTEM test with extrinsic activation of
coagulation; FIBTEM, ROTEM test with extrinsic activation of coagulation and platelet inhibition with cytochalasin D.ardiovascular Surgery c Volume 138, Number 3 697
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of bleeding was identified in any of the 4 patients.
ROTEM results in EXTEM and FIBTEM tests reflected
a gradual decrease in clot formation and firmness during
the operation (Table 3). After weaning from CPB, clotting
time in the INTEM test was 312  108.2 seconds (normal
range, 100–240 seconds), clot formation time was 210.5 
83.2 seconds (normal range, 30–110 seconds), MCF was
44  7.6 mm (normal range, 50–72 mm), and the alpha an-
gle was 60.2  9.2 (normal range, 70–83). After admin-
istration of fibrinogen concentrate, the clot formation and
firmness parameters improved in both the EXTEM and FIB-
TEM tests (Table 3 and Figure 2). The 24-hour postoperative
(first postoperative day) values were comparable with values
obtained after therapy and reflected satisfactory clot forma-
tion and firmness (Table 3). At baseline and 24 hours after
the operation, the results of standard laboratory analyses
were comparable between the 2 groups (Table 4).
DISCUSSION
In this study the use of fibrinogen concentrate was more
effective than FFP and PCs in achieving effective hemosta-
sis and reducing postoperative bleeding and also decreased
the use of allogeneic blood products in patients undergoing
TAAA operations.
Elective TAAA operations are associated with a high
mortality rate of 10.0% to 11.9%.5 Correction of intraoper-
ative coagulopathy, a cause of major blood loss that often
exceeds the patient’s intravascular volume,6 requires mas-
TABLE 1. Characteristics of patients undergoing thoracoabdominal
aortic aneurysm operations
Variable
Allogeneic
blood products,
group A (n ¼ 12)
Fibrinogen
concentrate,
group F (n ¼ 6)
Age (y), mean  SD 56.9  11.7 56.8  8.9
Weight (kg), mean  SD 73.2  23.4 81.2  18.9
Body mass index (kg/m2),
mean  SD
23.9  4.2 26.6  5.2
Female sex 5 (42%) 1 (17%)
Chronic pulmonary disease 5 (42%) 3 (50%)
Neurologic dysfunction 2 (17%) 2 (33%)
Previous cardiac surgery 5 (42%) 2 (33%)
Preoperative renal dysfunction 1 (8%) 0 (0%)
Moderate left ventricular dysfunction 0 (0%) 1 (17%)
Arterial hypertension 8 (67%) 5 (83%)
Diabetes (type 1 or 2) 1 (8%) 1 (17%)
Atrial fibrillation 2 (17%) 0 (0%)
Coronary heart disease 2 (17%) 1 (17%)
Peripheral vascular disease 3 (25%) 1 (17%)
Cerebrovascular disease 1 (8%) 0 (0%)
Preoperative renal dysfunction is defined as a creatinine value of greater than 200
mmol/L preoperatively. Moderate left ventricular dysfunction is defined as a left ven-
tricular ejection fraction of less than 30% to 50%. There were no statistically signif-
icant differences between groups. SD, Standard deviation.698 The Journal of Thoracic and Cardiovascular Sursive transfusion of blood products.9 In a study by Cambria
and associates,16 the requirement for blood products was
found to be an independent predictor of perioperative mor-
tality, which directly relates to the need to compensate for
acute massive bleeding and, probably to a far lesser extent,
to the complications of blood product transfusion. In the
quoted study survival rate was significantly correlated with
a higher platelet count at admission to the ICU, but the study
makes no reference to the changes in fibrinogen plasma con-
centration.16 The platelet count below which treatment for
bleeding is recommended varies in the literature.11,17 The re-
quirement for treatment of bleeding is influenced by various
factors, including premedication, use and type of ECC,
extension of the operation, and center-specific conditions.
The same is true for the amount of blood products that
should be administered in one therapy step to stop bleed-
ing.11,17 Transfusions of FFP and PCs are associated with
adverse outcomes in cardiac surgery.8,18 Furthermore, trans-
fusion of FFP can result in a number of volume-related
TABLE 2. Intraoperative and postoperative parameters in patients
undergoing thoracoabdominal aortic aneurysm operations
Variable
Allogeneic
blood products,
group A (n ¼ 12)
Fibrinogen
concentrate,
group F (n ¼ 6)
Intraoperative
Aortic clamp
time (min) mean  SD
96.7  58.3 97  24
CPB time (min) mean  SD 139.3  79.2 111  35
Deepest temperature
on CPB (C) mean  SD
34.1  1.2 34.4  0.9
Postoperative
ICU time to extubation (h),
mean  SD
42.9  36.3 18.5  14.7
ICU time (h), mean  SD 115.4  60.2 37  18.9*
Re-exploration for bleeding 4 (33%) 0 (0%)
Postoperative atrial fibrillation 1 (8%) 0 (0%)
Renal failure 2 (17%) 0 (0%)
Prolonged ventilatory support 5 (42%) 1 (17%)
Major neurologic events 2 (17%) 0 (0%)
30-d Mortality 2 (17%) 0 (0%)
Postoperative hospitalization (d) 12.2  5.2 14.0  8.4
Patients without any allogeneic
blood after CPB
0 (0%) 4 (66%)*
Units transfused/volume drained
after CPB and during the
first 24 h in ICU
Red blood cells (U), mean 4.1 1.0*
Fresh frozen plasma (U), mean 9.1 1.0*
Platelet concentrate (U), mean 3.2 0.5*
Total blood cell concentrates
(U), mean
16.4 2.5*
Drain volume (mL), mean 1093 449*
Prolonged ventilatory support is defined as ventilatory support for more than 40 hours.
SD, Standard deviation;CPB, cardiopulmonary bypass; ICU, intensive care unit. *Sig-
nificant difference, group F vs group A: Mann–Whitney U test, P< .05.gery c September 2009
Rahe-Meyer et al Perioperative ManagementTABLE 3. ROTEMvalues in patients undergoing thoracoabdominal aortic aneurysmoperations and treatedwith fibrinogen concentrate (groupF)
ROTEM variable Preoperative LS time point End CPB
After fibrinogen
concentrate therapy
First postoperative
day
EXTEM
CT (s; normal range, 38–79 s) 78.3  10.6 88.5  13.5 92.3  12.7 74.7  11.3 75.3  10.8
CFT (s; normal range, 34–159 s) 82.7  22.1 210.2  87.2 179.5  79.1 81.2  29 73.8  19.1
MCF (mm; normal range, 50–72 mm) 62.8  6.4 45.0  11.6 48.0  8.5 57.5  6.9 63.5  4.2
Alpha angle (; normal range, 63–83) 74.5  3.8 59.5  9.8 80.2  2.1 77  2.4
FIBTEM
MCF (mm; normal range, 9–25 mm) 17.2  5.9 7.7  4.3 8.3  4.5 22.7  5.5 24.2  4
Values are presented as the mean  standard deviation. ROTEM, Thromboelastometry; LS, last suture (the suture of the last collateral artery on the aortic graft); CPB, cardiopul-
monary bypass; EXTEM, ROTEM test with extrinsic activation of coagulation; CT, clotting time; CFT, clot formation time;MCF, maximum clot firmness; FIBTEM, ROTEM test
with extrinsic activation of coagulation and platelet inhibition with cytochalasin D.P
Madverse events, such as transfusion-related acute lung injury.
However, the number of units of RBCs transfused is the
leading predictor of length of hospital stay and complica-
tions after CPB surgery.19 In our study the administration
of fibrinogen concentrate as an initial therapy step in group
F before following the standard transfusion algorithm was
associated with a reduction in the transfusion not only of
PCs and FFP but also of RBCs in patients undergoing
TAAA surgery. These findings suggest a beneficial effect
of fibrinogen concentrate as hemostatic agent in this setting.
The introduction of therapy with fibrinogen concentrate did
not delay initiating the treatment algorithm because its prep-
aration fitted the timeframe usually required to order and
prepare FFP or PCs. Compared with the conventional
non–virus-inactivated allogeneic blood products, such as
FFP, cryoprecipitate, and PCs, the administration of fibrino-
gen concentrate might be time-saving by precluding thaw-
ing, cross-matching, or both. In our study administration
of fibrinogen concentrate was sufficient to stop bleeding in
all patients, and the remaining steps in the PC- and FFP-
based algorithm were not required.
The gravimetric measurement of blood loss was based on
the assumption that 1 mL of blood weighs 1 g, even though
the average specific gravity of red corpuscles is 1.0293 and
that of plasma is 1.0270.20 In a study by Johar and col-
leagues,21 measurement was performed by using dry surgi-
cal swabs that were weighed immediately after
contamination with blood to avoid loss through evaporation
and to accelerate the therapeutic decision. Careful surgical
hemostasis, including packing of the thorax and the abdo-
men with surgical swabs, is standard practice in TAAA sur-
gery. Thus major sources of bleeding usually do not go
undetected. In our study packing was restricted to exactly
5 minutes to accurately calculate the blood loss. Weighing
the surgical swabs after 5 minutes of packing might help dif-
ferentiate between excessive macrovascular and microvas-
cular bleeding, as well as between clinically relevant and
nonrelevant or ceased bleeding. A prospective trial that
uses a standardized method of assessment of the dryness
of the surgical field, such as the 5-minute blood loss method
presented in our study, might help clarify this aspect.The Journal of Thoracic and CFibrinogen concentrate was chosen for first-line hemo-
static therapy based on new research showing that low
perioperative fibrinogen concentrations correlate with bleed-
ing.4,12,22 In a multivariate analysis by Charbit and associ-
ates,23 fibrinogen was the only marker associated with the
occurrence of severe postpartum hemorrhage, with a 79%
negative predictive value of fibrinogen greater than 4 g/L
and a 100% positive predictive value of fibrinogen less
than 2 g/L. Heindl and coworkers24 previously described
the use of fibrinogen concentrate (7–8 g) as a hemostatic
agent in patients with major traumatic bleeding refractory
to standard coagulation therapy. Lower doses were shown
to improve clot formation in acquired hypofibrinogenemia
associated with cardiac surgery, liver transplantation,
trauma, and placental abruption; in dilutional coagulopathy
during complex orthopedic procedures; and in disseminated
intravascular coagulation as a result of massive blood loss
and transfusion.25-28 Applying these data to TAAA surgery,
we attempted to bring fibrinogen concentration after therapy
to a level characteristic for healthy subjects in the same age
group as our patients,13 a level also comparable with the pre-
operative level, and to see whether this would correct bleed-
ing and reduce the need for allogeneic blood products. The
timing of the hemostatic interventionwas chosen considering
that immediately after CPB with relatively normal duration
there would be enough thrombin generation and platelet ac-
tivity in the patients undergoing TAAA. According to the
findings of Hiippala and colleagues,29 fibrinogen concentra-
tionwould decrease to 1 g/L at 142%blood losswhen replac-
ing blood loss with plasma-poor RBC concentrate, but the
critically low levels of all other important coagulation ele-
ments (platelets and thrombin-generating coagulation fac-
tors, including Factor V) would only be reached after blood
loss of more than 200%. Regarding TAAA surgery, addi-
tional loss of fibrinogen might be caused by adhesion of fi-
brinogen and endothelial cells to the inner surface of the
graft after suture and perfusion30 and by bleeding at sutures.
At this level, the endogen effect of the plasmatic fibrinogen
can be compared with that of exogenous fibrinogen glue.31
The platelet count was decreased at the end of CPB.
However, even in the presence of thrombocytopenia,ardiovascular Surgery c Volume 138, Number 3 699
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centration near the platelet surface. A single thrombin mol-
ecule efficiently cleaves up to 1680 molecules of
fibrinogen,32 and therefore a low concentration of pro-
thrombin might not represent a limiting factor in clot for-
mation if sufficient fibrinogen is available. High
fibrinogen concentration might also compensate for the de-
creased platelet function in clot formation. There are ap-
proximately 40,000 to 80,000 copies of glycoprotein IIb/
IIIa receptors on a single activated platelet, and the number
of glycoprotein IIb/IIIa receptors on platelets remains rela-
tively constant after CPB.3 Even in the presence of throm-
bocytopenia, the extent of platelet–fibrin interactions can
be increased by high levels of fibrinogen. This was
TABLE 4. Standard laboratory data in patients undergoing
thoracoabdominal aortic aneurysm operations
Variable
Allogeneic
blood products,
group A (n ¼ 12)
Fibrinogen
concentrate,
group F (n ¼ 6)
Preoperative
Hemoglobin (g/dL; normal range,
13.5–17.5 g/dL)
13.8  1.6 12.9  1.1
Hematocrit (%; normal range
41.5%–50.4%)
39.8  4.1 38.1  3.0
PT (s; normal range, 11–13.5 s) 15.5  4.2 14.4  1.0
aPTT (s; normal range 26–35 s) 30.8  3.6 29.5  2.3
Platelet count (1000/mL; normal
range 150–450 3 1000/mL)
219.8  56.1 185.7  54.2
Fibrinogen (g/L; normal range,
2.0–4.5 g/L)
3.8  1.1 3.8  1.6
LS time point
Platelet count (1000/mL) – 92.5  37.3
End CPB
Hemoglobin (g/dL) – 9.3  1.0
Hematocrit (%) – 27.1  2.8
PT (s) – 25.4  2.0
aPTT (s) – 42  8.9
Platelet count (1000/mL) – 79.2  31.6
Fibrinogen (g/L) – 1.6  0.7
After therapy
Hemoglobin (g/dL) 10.4  1.4 9.8  1.6
Hematocrit (%) 30.7  3.8 28.3  4.6
PT (s) 17.2  1.3 25.8  4.5*
aPTT (s) 33.9  3.4 53.7  9.6*
Platelet count (1000/mL) 98.3  24.6 79.8  33.0
Fibrinogen (g/L) 2.5  0.7 3.6  1.0*
First postoperative day
Hemoglobin (g/dL) 10.7  1.0 10.3  1.0
Hematocrit (%) 31.7  3.2 30.7  3.1
PT (s) 17.4  2.8 18.1  1.5
aPTT (s) 36.8  10.0 46.2  14.9
Platelet count (1000/mL) 106.5  30.2 94.8  33.7
Fibrinogen (g/L) 4.4  0.9 4.6  1.1
Values are presented as the mean  standard deviation. PT, Prothrombin time; aPTT,
activated partial thromboplastin time; LS, last suture (the suture of the last collateral
artery on the aortic graft); CPB, cardiopulmonary bypass. *Significant difference,
group F vs group A: Mann–Whitney U test, P< .05.700 The Journal of Thoracic and Cardiovascular Surobserved in the present study by the increased EXTEM
MCF value after therapy with fibrinogen concentrate.
By increasing plasma fibrinogen levels to 3.6 g/L (or
10.7 mmol/L) in vivo, interactions between platelets,
thrombin, and fibrinogen appear to be improved. Correlat-
ing with this observation, hemostatic therapy with fibrino-
gen concentrate was more effective than therapy with
apheresis platelet transfusion in the presence of thrombocy-
topenia (platelet count<30 3 103/mm3) in a recent study
using the porcine hepatic laceration model.33
The decision to treat was not based on laboratory abnor-
malities of coagulation or bedside testing but on the clinical
observation ofmicrovascular bleeding. One safety parameter
was represented by the measurement of platelet counts at the
time point of the last suture to avoid inadequate transfusion
of PCs. However, sufficient correction of bleeding after
hemostatic therapy with fibrinogen made transfusion of
PCs unnecessary in group F. A second safety parameter
was represented by the calculation of the administered fibrin-
ogen dose based on the FIBTEM test because the test offers
a prompt readout of both the strength and the stability of the
fibrin clot.26,34 The FIBTEMMCF represents clot strength in
the presence of platelet inhibitor cytochalasin D.34 The
method has demonstrated good applicability in the operative
setting26,27 and good correlation to the plasma fibrinogen
concentration measured by using the standard laboratory
tests.35 The FIBTEM MCF at the end of CPB was less than
the lower limit of the normal range (normal, 9–25 mm) be-
cause the plasma fibrinogen concentration was reduced to
1.6 g/L in the prospective group (Table 4). The fibrinogen re-
pletion was guided by FIBTEM testing by using the empiric
target MCF of 22 mm. This strategy resulted in an average
MCF of 22.7 mm and a mean plasma fibrinogen concentra-
tion of 3.6 g/L (Tables 3 and 4). The FIBTEM test was per-
formed in whole blood and required no centrifugation of
the sample, a time-consuming step otherwise necessary in
the standard laboratory-based assessment of fibrinogen con-
centration. The decision for a fibrinogen concentrate therapy
had to be made within 10 minutes after CPB. The FIBTEM
MCFwas an ideal parameter for therapy management, being
obtained at the point-of-care site approximately 15 minutes
after the blood was drawn at the last suture time point. There-
fore FIBTEM MCF results were already available when
diffuse bleeding was diagnosed.
Calculation of fibrinogen dose based on FIBTEM has not
been described in the literature to date. EXTEM analysis,
performed both after therapy and 24 hours postoperatively
in the ICU, revealed median MCF values of less than 68
mm, the conservative upper limit set to avoid thrombotic
complications.14
The 2 groups of patients had comparable fibrinogen
values on the first postoperative day, suggesting that fibrin-
ogen concentrate therapy of diffuse bleeding after CPB re-
stored the hemostatic potential promptly, but the drug wasgery c September 2009
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main in circulation long enough to induce significantly
higher concentrations on the first postoperative day. It is
known that fibrin formation prevents systemic thrombotic
events by sequestering thrombin in the forming clot and
by reducing the catalytic activity of fibrin-bound thrombin.36
In agreement with these observations, group F did not pres-
ent more postoperative thrombotic complications than group
A. Notably, the duration of stay in the ICU was also reduced
in group F. These findings might be relevant to the assess-
ment of the safety of fibrinogen concentrate administration
in this setting. In addition, despite the lower transfusion of
RBCs, FFP, and PCs in the fibrinogen therapy group, the
laboratory data on hematocrit values, platelet counts, pro-
thrombin time/activated partial thromboplastin time values,
and fibrinogen concentrations were comparable between the
groups at 24 hours postoperatively, suggesting that FIB-
TEM-guided fibrinogen therapy was associated with satis-
factory correction of hemostasis.
All patients in groups A and F received aprotinin; how-
ever, this product is no longer available, and subsequent
patients undergoing TAAA operations in our clinic after
study completion received tranexamic acid.
The main limitation of the study was that the groups con-
sisted of complete consecutive cohorts and the patients were
not randomized to the type of hemostatic therapy received.
There were also differences in the preoperative status of pa-
tients (eg, more female patients and lower mean body weight
in group A), which, although nonsignificant, might have
been associated with a higher risk of bleeding. The higher
bypass times in the retrospective group, again nonsignifi-
cant, might also have had an effect on the hemostatic defects
and the associated transfusion requirements in this group.
However, group A had higher platelet counts at all times
and better posttherapy coagulation parameters, except for
fibrinogen plasma concentration. After correction of most
coagulation parameters, the retrospective group still re-
quired significantly higher transfusion while in the ICU
based on the drainage volume and the persistent blood loss.
Our findings indicate that coagulation therapy with fibrin-
ogen concentrate might reduce the high use of allogeneic
blood products and postoperative bleeding in patients under-
going TAAA surgery. To our knowledge, this was the first
time that a fibrinogen level of 3.6 g/L, in the higher normal
range, was targeted. The FIBTEM MCF appeared to be an
appropriate parameter for dosage of fibrinogen concentrate.
The clinical value of these data is limited by the low number
of patients and the nonrandomized study design. However,
the data are encouraging and suggest that this hypothesis
should be examined in a prospective, randomized, double-
blind, placebo-controlled clinical trial in this setting.
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